Pharmamarketeer
overig

Boehringer’s Gilotrif approved in US for lung cancer with non-resistant EGFRs

19 januari 2018
Pharmafile

Boehringer Ingelheim is celebrating the FDA’s decision to expand the indication of its lung cancer drug Gilotrif (afatinib) to include the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have non-resistant epidermal growth factor receptor (EGFRs).

Reageer

Ook interessant voor je

Medhc-fases-banner
Advertentie(s)